Zoledronic acid concurrent with either high- or reduced-dose palliative radiotherapy in the management of the breast cancer patients with bone metastases: a phase IV randomized clinical study

被引：0
|
作者：
Lale Atahan
Ferah Yıldız
Mustafa Cengiz
Bunyamin Kaplan
Metin Özkan
Gozde Yazici
Mete Gündoğ
Ayfer Haydaroğlu
Aylin F. Korcum
Meriç Şengöz
Maktav Dinçer
Müge Akmansu
Kayıhan Engin
Mutlu Hayran
机构：
[1] Hacettepe University,Department of Radiation Oncology
[2] Erciyes University,Department of Radiation Oncology
[3] Ankara Education and Investigation Hospital of Ministry of Health,Department of Radiation Oncology
[4] Ege University,Department of Radiation Oncology
[5] Akdeniz University,Department of Radiation Oncology
[6] Marmara University,Department of Radiation Oncology
[7] İstanbul University,Department of Radiation Oncology
[8] Gazi University,Department of Radiation Oncology
[9] Uludağ University,Department of Radiation Oncology
[10] Anadolu Sağlık Merkezi,Department of Preventive Oncology
[11] Hacettepe University,undefined
来源：
Supportive Care in Cancer | 2010年 / 18卷
关键词：
Bone metastasis; Breast cancer; Radiotherapy; Zoledronic acid;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：691 / 698
页数：7
相关论文
共 50 条
  • [21] Prognostic and predictive value of clinical and biochemical factors in breast cancer patients with bone metastases receiving "metronomic" zoledronic acid
    Xinmin Zhao
    Xiaofeng Xu
    Qunling Zhang
    Zhen Jia
    Si Sun
    Jian Zhang
    Biyun Wang
    Zhonghua Wang
    Xichun Hu
    BMC Cancer, 11
  • [22] A pilot phase II study of concurrent capesitabine (Xelodatm) and external beam radiotherapy for bone metastases of breast cancer origin
    Kundel, Y.
    Yerushalmi, R.
    Fenig, E.
    Pfeffer, R.
    Stemmer, S.
    Rizel, S.
    Symon, Z.
    Kaufman, B.
    Sulkes, A.
    Brenner, B.
    RADIOTHERAPY AND ONCOLOGY, 2006, 81 : S426 - S427
  • [23] Phase II Study of Concurrent Capecitabine and External Beam Radiotherapy for Pain Control of Bone Metastases of Breast Cancer Origin
    Kundel, Yulia
    Nasser, Nicola J.
    Purim, Ofer
    Yerushalmi, Rinat
    Fenig, Eyal
    Pfeffer, Raphael M.
    Stemmer, Salomon M.
    Rizel, Shulamith
    Symon, Zvi
    Kaufman, Bella
    Sulkes, Aaron
    Brenner, Baruch
    PLOS ONE, 2013, 8 (07):
  • [24] Phase III trial of oral ibandronate and intravenous zoledronic acid in breast cancer patients with bone metastases:: comparison of bone turnover markers
    Lichinitser, M.
    Coleman, R. E.
    Tjulandin, S. A.
    Bergstrom, B.
    Body, J.-J.
    EJC SUPPLEMENTS, 2005, 3 (02): : 113 - 113
  • [25] EFFECT OF DENOSUMAB VERSUS ZOLEDRONIC ACID ON OVERALL SURVIVAL IN PATIENTS WITH LUNG CANCER AND BONE METASTASES: RESULTS FROM A RANDOMIZED PHASE 3 STUDY
    Scagliotti, G.
    Woll, P.
    Manegold, C.
    Solal-Celigny, P.
    Lipton, L.
    Garcia-Saenz, J. A.
    Pereira, J. R.
    Prabhash, K.
    Ciuleanu, T.
    Jacobs, I.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (06) : S61 - S62
  • [26] A phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal related event (SRE) or progressive bone metastases despite standard bisphosphonate (BP) therapy
    Clemons, M
    Dranitsaris, G
    Ooi, WS
    Cole, DEC
    BONE, 2006, 38 (03) : S71 - S71
  • [27] Results of a prospective, randomized, double-blind, double-dummy, Phase 3 study comparing denosumab with zoledronic acid for the treatment of breast cancer patients with bone metastases
    Body, Jean-Jacques
    Stopeck, Alison
    Fujiwara, Yasuhiro
    Lipton', Allan
    Steger, Guenther
    Viniegra, Maria
    Fan, Michelle
    Dansey, Roger
    Susie, Jun
    Ada, Braun
    BONE, 2010, 46 : S36 - S37
  • [28] Effects on bone resorption markers of continuing pamidronate or switching to zoledronic acid in patients with high risk bone metastases from breast cancer
    Hilton, J. F.
    Clemons, M.
    Pond, G.
    Zhao, H.
    Mazzarello, S.
    Vandermeer, L.
    Addison, C. L.
    JOURNAL OF BONE ONCOLOGY, 2018, 10 : 6 - 13
  • [29] Cost-effectiveness of oral ibandronate versus iv zoledronic acid or iv pamidronate in the treatment of breast cancer with bone metastases in patients undergoing iv chemotherapy in the UK
    De Cock, E
    Hutton, J
    Barrett-Lee, P
    Canney, P
    Body, JJ
    Neary, M
    Lewis, GJ
    VALUE IN HEALTH, 2004, 7 (06) : 672 - 672
  • [30] Computed tomography (CT) evaluation of breast cancer patients with osteolytic bone metastases undergoing palliative radiotherapy - a feasibility study
    Chow, E
    Holden, L
    Rubenstein, J
    Christakis, M
    Sixel, K
    Vidmar, M
    Finkelstein, J
    Hayter, C
    Loblaw, A
    Wong, R
    Szumacher, E
    Danjoux, C
    RADIOTHERAPY AND ONCOLOGY, 2004, 70 (03) : 291 - 294
12345